First Header Logo Second Header Logo

Reza Ghasemi

TitleAssistant Professor
InstitutionWake Forest School of Medicine
DepartmentPathology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ghasemi R, Corliss MM, Bowling KM, Krysiak K, Walker J, Dickson AM, Schroeder MC, Parikh BA, Neidich JA, Polonis K, Cao Y. Comprehensive Analysis of TEK Variants in Patients With Vascular Malformations. Clin Genet. 2024 Dec 04. PMID: 39632338.
      Citations:    
    2. Vaseghi P, Habibi L, Neidich JA, Cao Y, Fattahi N, Rashidi-Nezhad R, Salehnezhad T, Dalili H, Rahimi Sharbaf F, Zarkesh MR, Malekian M, Mokhberdezfuli M, Mehrtash A, Ardeshirdavani A, Kariminejad R, Ghorbansabagh V, Sadeghimoghadam P, Naddaf A, Esmaeilnia Shirvany T, Mosayebi Z, Sahebdel B, Golshahi F, Shirazi M, Shamel S, Moeini R, Heidari A, Daneshmand MA, Ghasemi R, Akrami SM, Rashidi-Nezhad A. Towards solving the genetic diagnosis odyssey in Iranian patients with congenital anomalies. Eur J Hum Genet. 2024 Oct; 32(10):1238-1249. PMID: 38278869.
      Citations:    
    3. Ghasemi R, Trammel C, Jensen N, Stanley A, Smith S, Schroeder M, Neidich J, Shinawi M, Jackson S, Polonis K. P697: Prenatal diagnosis and postnatal clinical course of a fetus with low-level mosaic trisomy 17q. Genetics in Medicine Open. 2024; 2. View Publication.
    4. Slade MJ, Ghasemi R, O'Laughlin M, Burton T, Fulton RS, Abel HJ, Duncavage EJ, Ley TJ, Jacoby MA, Spencer DH. Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing. JCO Precis Oncol. 2023 Apr; 7:e2200559. PMID: 37079859.
      Citations:    
    5. Ghasemi R, Corliss M, Krysiak K, Parikh B, Dickson A, Bowling K Schroeder M, Heusel J, Neidich J, Cao Y. P468: A comparative analysis of TEK variants in patients with vascular anomalies. Genetics in Medicine Open. 2023; 1(1). View Publication.
    6. Ghasemi R, Struthers H, Wilson ER, Spencer DH. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia. 2021 Feb; 35(2):404-416. PMID: 32398790.
      Citations:    
    7. Ghasemi R, Heidi S, Spencer D. Homozygous Loss of a Critical CTCF Recognition Sequence in the HOXA gene Cluster Eliminates CTCF Binding but Does Not Appreciably Reduce HOXA9 expression in NPM1 Mutated AML Cells. Blood. 2018; 132. View Publication.
    8. Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, Sabourinejad Z, Alishahi Z, Yousefi H, Ghasemi R, Dardaei L, Bashash D, Chahardouli B, Dehpour AR, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 2017 Jun 23; 7(1):4204. PMID: 28646172.
      Citations:    
    9. Lazear E, Ghasemi R, Hein SM, Westwick J, Watkins D, Fremont DH, Krupnick AS. Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. Oncoimmunology. 2017; 6(2):e1265721. PMID: 28344875.
      Citations:    
    10. Arefanian S, Schäll D, Chang S, Ghasemi R, Higashikubo R, Zheleznyak A, Guo Y, Yu J, Asgharian H, Li W, Gelman AE, Kreisel D, French AR, Zaher H, Plougastel-Douglas B, Maggi L, Yokoyama W, Beer-Hammer S, Krupnick AS. Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance. Oncoimmunology. 2016; 5(12):e1238543. PMID: 28123874.
      Citations:    
    11. Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, Krupnick AS. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun. 2016 Sep 21; 7:12878. PMID: 27650575.
      Citations:    
    12. Lupini L, Pepe F, Ferracin M, Braconi C, Callegari E, Pagotto S, Spizzo R, Zagatti B, Lanuti P, Fornari F, Ghasemi R, Mariani-Costantini R, Bolondi L, Gramantieri L, Calin GA, Sabbioni S, Visone R, Veronese A, Negrini M. Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget. 2016 May 24; 7(21):31361-71. PMID: 27120784.
      Citations:    
    13. Momeny M, Ghasemi R, Valenti G, Miranda M, Zekri A, Zarrinrad G, Javadikooshesh S, Yaghmaie M, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway. Tumour Biol. 2016 Mar; 37(3):3913-23. PMID: 26482609.
      Citations:    
    14. Sala G, Ghasemi R, Capone E, Rapposelli I, Traini S, Rossi C, Natali P, Iacobelli S. Abstract 5437: Dual targeting of ErbB-2 and ErbB-3: A new potential strategy for the treatment of pancreatic cancer. Cancer Research. 2014; 74(19). View Publication.
    15. Lattanzio R, Ghasemi R, Brancati F, Sorda RL, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali PG, Piantelli M. Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. Oncogenesis. 2014; 3. View Publication.
    16. Ghasemi R, Rapposelli G, Capone E, Rossi C, Lattanzio R, Piantelli M, Sala G, Iacobelli S. Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogenesis. 2014. View Publication.
    17. Sala G, Rapposelli IG, Ghasemi R, Piccolo E, Traini S, Capone E, Rossi C, Pelliccia A, Di Risio A, D'Egidio M, Tinari N, Muraro R, Iacobelli S. EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Transl Oncol. 2013 Dec 01; 6(6):676-84. PMID: 24466370.
      Citations:    
    18. Ghasemi R, Ghaffari SH, Momeny M, Pirouzpanah S, Yousefi M, Malehmir M, Alimoghaddam K, Ghavamzadeh A. Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells. Nutr Cancer. 2013; 65(4):590-9. PMID: 23659451.
      Citations:    
    19. Ghasemi R, Grassadonia A, Tinari N, Piccolo E, Natoli C, Tomao F, Iacobelli S. Tumor-derived microvesicles: the metastasomes. Med Hypotheses. 2013 Jan; 80(1):75-82. PMID: 23177570.
      Citations:    
    20. Momeny M, Malehmir M, Zakidizaji M, Ghasemi R, Ghadimi H, Shokrgozar M, Emami A, Nafissi S, Ghavamzadeh A, Ghaffari S. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anti-Cancer Drugs. 2010; 3(21). View Publication.
    21. Momeny, M., Ghasemi, R., Ghaffari, S. H., Nejati, M. R., Mojarrad, M., Yousefi, M., Dehpour, A. R. Emami, A. H. . Annals of Oncology. INHIBITORY EFFECTS OF SILIBININ ON INVASIVE PROPERTIES OF HUMAN BREAST CANCER CELL LINE MDA-MB-231 THROUGH SUPPRESSION OF THE PROTEOLYTIC CASCADE OF CATHEPSIN B/UROKINASE-TYPE PLASMINOGEN ACTIVATOR/MATRIX METALLOPROTEINASE 9. 2010.
    22. Momeny M, Malehmir M, Zakidizaji M, Ghasemi R, Ghadimi H, Shokrgozar MA, Emami AH, Nafissi S, Ghavamzadeh A, Ghaffari SH. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs. 2010 Mar; 21(3):252-60. PMID: 20166242.
      Citations:    
    23. Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep; 27(3):833-42. PMID: 19763917.
      Citations:    
    24. Momeny M, Zakidizaji M, Ghasemi R, Mirzaeekhalilabadi R, Mardanivalandani H, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH. 9241 Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription. 2009. View Publication.
    Same Department Expand Description
    Explore
    _